552 related articles for article (PubMed ID: 10705303)
1. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
3. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients.
Kümpfel T; Schwan M; Pollmächer T; Yassouridis A; Uhr M; Trenkwalder C; Weber F
Mult Scler; 2007 Nov; 13(9):1138-45. PubMed ID: 17967841
[TBL] [Abstract][Full Text] [Related]
4. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
[TBL] [Abstract][Full Text] [Related]
5. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis.
Muzaffer MA; Dayer JM; Feldman BM; Pruzanski W; Roux-Lombard P; Schneider R; Laxer RM; Silverman ED
J Rheumatol; 2002 May; 29(5):1071-8. PubMed ID: 12022325
[TBL] [Abstract][Full Text] [Related]
6. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients.
Rogy MA; Coyle SM; Oldenburg HS; Rock CS; Barie PS; Van Zee KJ; Smith CG; Moldawer LL; Lowry SF
J Am Coll Surg; 1994 Feb; 178(2):132-8. PubMed ID: 8173722
[TBL] [Abstract][Full Text] [Related]
7. Soluble receptors and cytokine antagonists in human milk.
Buescher ES; Malinowska I
Pediatr Res; 1996 Dec; 40(6):839-44. PubMed ID: 8947960
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity.
Gabay C; Cakir N; Moral F; Roux-Lombard P; Meyer O; Dayer JM; Vischer T; Yazici H; Guerne PA
J Rheumatol; 1997 Feb; 24(2):303-8. PubMed ID: 9034987
[TBL] [Abstract][Full Text] [Related]
9. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
[TBL] [Abstract][Full Text] [Related]
10. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.
Ribbens C; André B; Kaye O; Kaiser MJ; Bonnet V; de Groote D; Franchimont N; Malaise MG
Eur Cytokine Netw; 2000 Dec; 11(4):669-76. PubMed ID: 11125312
[TBL] [Abstract][Full Text] [Related]
11. [Changes of proinflammatory cytokines and their receptors in serum from patients with pulmonary tuberculosis].
Tang S; Xiao H; Fan Y; Wu F; Zhang Z; Li H; Yang Y
Zhonghua Jie He He Hu Xi Za Zhi; 2002 Jun; 25(6):325-9. PubMed ID: 12126553
[TBL] [Abstract][Full Text] [Related]
12. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of cytokine regulation in discrete clinical forms of Plasmodium falciparum malaria.
Akanmori BD; Kurtzhals JA; Goka BQ; Adabayeri V; Ofori MF; Nkrumah FK; Behr C; Hviid L
Eur Cytokine Netw; 2000 Mar; 11(1):113-8. PubMed ID: 10705308
[TBL] [Abstract][Full Text] [Related]
14. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J
Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
[TBL] [Abstract][Full Text] [Related]
15. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia.
Schmid I; Schmitt M; Streiter M; Meilbeck R; Haas RJ; Stachel DK
Eur J Med Res; 2005 Nov; 10(11):457-61. PubMed ID: 16354598
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
17. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
[TBL] [Abstract][Full Text] [Related]
18. Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF.
Hübel K; Mansmann G; Schäfer H; Oberhäuser F; Diehl V; Engert A
Cytokine; 2000 Dec; 12(12):1797-800. PubMed ID: 11097751
[TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory cytokine levels in patients with septic shock.
Kasai T; Inada K; Takakuwa T; Yamada Y; Inoue Y; Shimamura T; Taniguchi S; Sato S; Wakabayashi G; Endo S
Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):34-42. PubMed ID: 9434313
[TBL] [Abstract][Full Text] [Related]
20. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
